Skip to main content

Diagnos Inc(ADK-X)
TSX Venture

Today's Change
Delayed Last Update

DIAGNOS and the CHUM are launching the testing phase of autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening

Globe Newswire - Thu May 26, 2022

BROSSARD, Quebec, May 26, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce, in partnership with the Centre hospitalier de l’Université de Montréal (CHUM), the launch of the testing phase for autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market
Short sales on the TSX: What bearish investors are betting against
Larry MacDonald